ctDNA Methylation for Detecting Ovarian Cancer

Launched by LEI LI · Mar 24, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating a new method to detect ovarian cancer using a simple blood test. Researchers are focusing on specific changes in DNA—called methylation—that can indicate the presence of ovarian cancer. Early detection is crucial because it significantly increases the chances of successful treatment, but many women are diagnosed at a late stage. By examining the levels of certain genes in the blood, this study aims to improve how we identify ovarian cancer and its precursors, potentially leading to better outcomes for patients.

To participate in the trial, women aged 18 and older who are preparing for surgery for a pelvic or adnexal mass may be eligible. Participants should not have received chemotherapy or surgery for ovarian issues before the trial and must be willing to provide blood samples for testing. The study will involve multiple centers and aims to enroll over 1,400 participants, comparing the blood test results with traditional methods of diagnosing ovarian cancer. Those involved can expect to contribute to important research that could change how ovarian cancer is detected in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Patients ready for surgical treatment for pelvic mass or adnexal mass
• • Age is greater than or equal to 18 years
• • Not receiving any chemotherapy, physical therapy, or surgical treatment for ovarian lesions
• • With ovarian pathology
• • Willing to be tested and signed an informed consent form
• • With available data of plasma CA125, Human epididymis protein 4 and effective imaging results
• • The study will also enroll several patients with primary breast cancer, lung cancer, colon cancer, uterine cervical cancer and uterine carcinomas
• Exclusion Criteria:
• • Not meeting all the including criteria
• • A sample of patients withdrawing from the trial
• • Samples that the investigator believes should be excluded from this trial